Follistatin Dosage: Protocols, Cycle Length, and Why Less Is More

The starting dose is small. Most experienced users begin at 100 mcg of follistatin subcutaneously once daily, for a 10 to 14-day cycle, before deciding whether to extend.

That single line carries you further than most articles let on. The rest of this guide builds the cycle around it.

Follistatin dosage chart by goal

Pick the row that matches your context. These dosing tiers come from community protocols, peptide-clinic guidance, and gene-therapy dose extrapolation.

For broader context on what follistatin is doing during a cycle, see what follistatin is and follistatin 344.

Why the starting dose is so low

Conservative first. Follistatin is expensive, the human peptide pharmacokinetic data is thin, and side-effect surveillance lives mostly in forum reports.

A 10 to 14-day trial at 100 mcg per day gives you three things at low cost:

1. A real read on your individual response, including injection-site reactions and any visual changes
2. A measurable strength and bodyweight change against your normal training trend
3. A baseline for deciding whether to extend to 20 or 30 days at the same dose

Many experienced users find that 100 mcg for 14 days is enough to spark a satellite-cell response, and that doubling the dose mostly doubles cost without doubling outcome.

Dose by goal in plain language

The table above is the framework. The reasoning underneath:

Muscle growth. The 100 to 200 mcg per day range was settled in community use because it spans the rough pharmacokinetic window predicted from gene-therapy expression data. Anything above 300 mcg per day adds unknowns more than it adds size.

Pre-workout targeting. The 50 mcg pre-training intramuscular protocol concentrates exposure around training stimulus. The logic is straightforward: target myostatin inhibition when satellite cell activation is highest. Long-term efficacy data is limited.

Sarcopenia and aging. Lower doses for longer periods make more sense here. The goal is sustained low-level pathway support paired with resistance training, not maximal acute exposure. Discuss with a clinician first; the safety profile in older adults has more unknowns than gains.

Stacks. Pairing follistatin with BPC-157, IGF-1 LR3, or a GH secretagogue is common in forum protocols. None of these stacks have controlled human evidence. Start with follistatin alone first to isolate your response.

Route, frequency, and timing

Subcutaneous is the default. Most cycles use a 29 to 31-gauge insulin syringe into abdominal fat, with rotating sites to reduce irritation.

Intramuscular injection is the alternative. Some protocols deliver into the muscle being targeted (vastus lateralis, deltoid, gluteus medius) on the theory that local tissue exposure matters; the data is mostly anecdotal.

Timing matters less than consistency:

• Once-daily dosing at roughly the same time each day
• Pre-workout (30 minutes before training) for the IM training-day protocol
• Never split a dose into more than two injections unless using FLGR242 or a longer-acting analog

Reconstitution math for a 1 mg vial

Here is the math no one explains the first time. Follistatin is shipped as a freeze-dried (lyophilized) powder, typically in 1 mg vials.

Reconstitution rules that prevent ruined vials:

1. Add bacteriostatic water down the side of the vial, never directly onto the powder
2. Swirl gently for 2 to 5 minutes until clear; never shake
3. Refrigerate at 2 to 8 °C after reconstitution; do not freeze
4. Use within 14 to 21 days; discard if cloudy or particulate
5. Store unreconstituted powder at -20 °C for long-term stability

Missed-dose handling and adjustments

Missed doses happen. The simple rules:

• If you remember within 12 hours, take the dose and continue normally
• If it has been more than 12 hours, skip and resume the next day; do not double up
• If you miss three or more consecutive days, treat the cycle as paused and decide whether to continue or end early
• If side effects appear (visual changes, severe injection-site reaction, mood changes), stop immediately and consult a clinician

For visual symptoms specifically, stop and see an ophthalmologist before resuming. The 11 reported central serous chorioretinopathy cases came from high single doses, but smaller cumulative exposure has not been mapped.

Cycle length and off periods

Short cycles are the standard. Most protocols cap at 30 days, with most users running 10 to 21 days per cycle.

The off period is doing real work:

• Satellite cells need weeks to fully differentiate and fuse with existing fibers
• Activin pathway homeostasis (FSH, reproductive signaling) can normalize
• Cardiac myostatin signaling rests after systemic exposure
• The off period reveals which gains are real and durable versus transient pump and water

A reasonable annual ceiling is two to three cycles per year. More than that has no efficacy basis and increases cost, regulatory risk, and unknown safety load.

When to use less than the table

Less is the right call in several situations:

• First-ever cycle: 100 mcg for 10 days only, regardless of long-term plan
• Light bodyweight (under 70 kg): start at 100 mcg, not 200
• Higher body fat: subcutaneous absorption is more variable; consider 100 mcg consistently before pushing higher
• History of any retinal disease, even mild: do not begin without ophthalmology clearance
• Female users planning fertility within 12 months: avoid cycles given FSH suppression risk

For the safety detail, see follistatin side effects. For lifestyle alternatives, see how to increase follistatin naturally and natural myostatin inhibitor.

Sources and notes

• Follistatin Dosage Guide — MyPeptideMatch
• Follistatin 344 Dosage Guide — PeptideWiki
• Follistatin-344 Dosing: 50 mcg Pre-Workout Protocol — The Peptide Catalog
• Follistatin Protocol: Dosing and Cycle Guide — The Peptide Guides
• Follistatin 344: Dosage, Buying, Benefits, Uses — Muscle and Brawn
• Follistatin 344 Peptide — Jay Campbell
• Phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy
• Central serous chorioretinopathy associated with high-dose follistatin-344

Frequently Asked Questions